Observation Versus Immediate Surgery of Low Risk Bladder Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02700724 |
Recruitment Status :
Terminated
(poor enrollment)
First Posted : March 7, 2016
Last Update Posted : August 13, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bladder Cancer | Other: Immediate Surgery Other: Observation Procedure: Surveillance Cystoscopy and Urinary Cytology | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 8 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Observation Versus Immediate Surgery of Low Risk Bladder Cancer |
Study Start Date : | April 2016 |
Actual Primary Completion Date : | July 19, 2018 |
Actual Study Completion Date : | July 19, 2018 |
Arm | Intervention/treatment |
---|---|
Observation
Patients will not undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Surgery will commence after 12 months of observation or sooner if cystoscopic evidence of disease progression or patient desire.
|
Other: Observation
Other Name: Active Surveillance Procedure: Surveillance Cystoscopy and Urinary Cytology Cytology and cystoscopy are done at the same time |
Immediate Surgery
Patients will undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Repeated surgery will be offered for additional recurrences.
|
Other: Immediate Surgery
Other Name: Transurethral Resection of Bladder Tumor Procedure: Surveillance Cystoscopy and Urinary Cytology Cytology and cystoscopy are done at the same time |
- Event-Free Survival [ Time Frame: 12 months ]An event is a complication of any kind, including bleeding requiring blood transfusion, bladder perforation, urinary tract infection, readmission to the hospital, and progression of disease.
- Proportion of patients with disease progression (either stage or grade) [ Time Frame: 12 months ]proportion of patients with disease progression (either stage or grade)
- Patient-reported Costs [ Time Frame: At baseline and 3 months, 6 months, 9 months and 12 months. ]out of pocket medical costs
- Self-reported patient anxiety measured using the EORTC QLQ-NMIBC24 [ Time Frame: At baseline and 3 months, 6 months, 9 months and 12 months. ]Measured using the EORTC QLQ-NMIBC24, which is a 24-item questionnaire for patients with superficial bladder cancer. This will be assessed at baseline and every 3 months during the study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- History of low grade, noninvasive urothelial carcinoma of the bladder with a new recurrence that meets the following criteria:
- total tumor burden ≤3cm in size (multiple lesions permitted)
- low grade appearance (grade 1 or grade 2)
- noninvasive appearance (Ta)
- no history of carcinoma in situ (CIS) or lesions concerning for CIS
- negative urine cytology (atypical or suspicious for low grade neoplasm are acceptable)
Exclusion Criteria:
- High grade and/or invasive and/or carcinoma in situ disease
- Concomitant upper tract urothelial carcinoma
- Any patient who is pregnant or who may have plans to become pregnant.
- Positive cytology
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02700724
United States, Tennessee | |
Vanderbilt University Medical Center | |
Nashville, Tennessee, United States |
Principal Investigator: | Daniel D. Lee, MD | Vanderbilt University Medical Center |
Responsible Party: | Daniel Lee, Instructor, Vanderbilt University Medical Center |
ClinicalTrials.gov Identifier: | NCT02700724 |
Other Study ID Numbers: |
151898 |
First Posted: | March 7, 2016 Key Record Dates |
Last Update Posted: | August 13, 2018 |
Last Verified: | August 2018 |
Urinary Bladder Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Female Urogenital Diseases |
Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Urinary Bladder Diseases Urologic Diseases Male Urogenital Diseases |